

WD CEF 1042  
box SE or

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 19 1999


In re Patent Application of

Gray et al.

Serial No.: 08/892,695

Filed: 07/15/97

For: GENES FROM THE 20q13  
AMPLICON AND THEIR USES



Group Art Unit: 1642

Examiner:  
Johnson, N.

San Francisco, California

Assistant Commissioner for Patents  
Washington, D.C. 20231

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail  
in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

Aug. 11, 1999

Sandy Ellsworth

Sandy Ellsworth

Signature

8/11/99  
Date

AMENDMENT TRANSMITTAL

Sir:

Transmitted herewith, in response to the Examiner's Communication mailed July 2, 1999, are the following items:

- 1) An Amendment;
- 2) A computer readable copy of the Sequence Listing;
- 3) A substitute paper copy of the Sequence Listing;

- 4) A request for a 1-month extension of time in which to respond to the Examiner's Communication; and
- 5) A check in the amount of \$110 is enclosed to cover the fee for the extension of time.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 13-1030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Dated: 8/11/99

Atty. Docket: 2500.124US3



Tom Hunter (Reg. No. 38,498)  
MAJESTIC, PARSONS, SIEBERT & HSUE P.C.  
Four Embarcadero Center, Suite 1100  
San Francisco, California 94111-4106  
Telephone: (415) 248-5500  
Facsimile: (415) 362-5418

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).  
*Not in proper format*
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- 7.

Other: \_\_\_\_\_

**Applicant must provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"  
*in proper format*
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400



Please return a copy of this notice with your response.